Last reviewed · How we verify
NCT05909943
Efficacy and Safety of Ruxolitinib in Neuromyelitis Optica Spectrum Disorders
Phase 1, PHASE2 trial testing Ruxolitinib in Neuromyelitis Optica Spectrum Disorder Relapse. Withdrawn.
1 February 2026
Quick facts
| Lead sponsor | Tianjin Medical University General Hospital |
|---|---|
| Phase | Phase 1, PHASE2 |
| Status | Withdrawn |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | basic science |
| Start date | 1 June 2024 |
| Primary completion | 1 February 2026 |
| Estimated completion | 1 August 2026 |
| Sites | 1 location across China |
Drugs / interventions tested
- Ruxolitinib (RUXOLITINIB) — full drug profile →
Conditions studied
- Neuromyelitis Optica Spectrum Disorder Relapse — all drugs for Neuromyelitis Optica Spectrum Disorder Relapse →
Sponsor
Tianjin Medical University General Hospital
Who can join
18 and older, any sex, with Neuromyelitis Optica Spectrum Disorder Relapse. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Neuromyelitis Optica Spectrum Disorders (NMOSD) is associated with a pathological humoral immune response against the aquaporin-4(AQP-4) water channel. Rucotinib is an oral inhibitor of JAK1 and JAK2 tyrosine kinases. It may benefit some patients with NMOSD due to the important role of JAK/STAT signaling pathway in the pathogenesis of NMOSD. Clincial trials may be needed to observe its efficacy and safety.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05909943
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Ruxolitinib
Trials testing the same drug.
- NCT07498205 — Comparing Momelotinib and Ruxolitinib in People With Untreated Myelofibrosis and Low Blood Cell Counts · Phase 4 · not yet recruiting
- NCT07249346 — Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease ( · Phase 2 · recruiting
- NCT07311746 — Phase Ib/II Trial of Cladribine/Ruxolitinib/Venetoclax in Patients With Relapsed/Refractory T-cell Prolymphocytic Leukem · Phase 1, PHASE2 · not yet recruiting
- NCT07340138 — Study of Pelabresib add-on to Ruxolitinib in Japanese Adult Patients With Myelofibrosis · Phase 1 · not yet recruiting
- NCT07424222 — Ruxolitinib for Immune Effector Cell Associated Hemophagocytic Lymphohistiocytosis-like Syndrome (RISE) · Phase 1 · not yet recruiting
Other Tianjin Medical University General Hospital trials
Trials by the same sponsor.
- NCT06228781 — Autologous Hematopoietic Stem Cell Transplantation for Refractory Multiple Sclerosis · NA · not yet recruiting
- NCT07498595 — TILs Plus Third-Generation EGFR-TKI Therapy for TKI-Resistant NSCLC · EARLY_PHASE1 · not yet recruiting
- NCT07498439 — TILs Therapy for Multiple Primary Early-Stage NSCLC · EARLY_PHASE1 · not yet recruiting
- NCT07018375 — The Effect of Oliceridine Patient-Controlled Intravenous Analgesia on Postoperative Chronic Pain After Video-Assisted Th · Phase 4 · not yet recruiting
- NCT07420296 — Modified Zipper Therapy for AQP4-IgG Positive Neuromyelitis Optica Spectrum Disorder · Phase 3 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05909943 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Tianjin Medical University General Hospital
- Last refreshed: 18 June 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05909943.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing